PDF Archive

Easily share your PDF documents with your contacts, on the Web and Social Networks.

Share a file Manage my documents Convert Recover PDF Search Help Contact

Statistical Analysis Plan .pdf

Original filename: Statistical Analysis Plan.pdf
Author: Bosch

This PDF 1.4 document has been generated by Acrobat PDFMaker 9.1 for Word / Adobe PDF Library 9.0, and has been sent on pdf-archive.com on 24/01/2018 at 23:25, from IP address 76.88.x.x. The current document download page has been viewed 493 times.
File size: 91 KB (1 page).
Privacy: public file

Download original PDF file

Document preview

Statistical Analysis Plan
Pilot Study Evaluating the Efficacy of Certolizumab Pegol for Interstitial

Sample size
Previous IC/BPS studies demonstrated an approximate 20% placebo response rate [29].
Monotherapy response rate of certolizumab pegol in rheumatoid arthritis was 45% [21]. To
achieve an 80% power using 2:1 randomization and a 2-sided p = .05 a minimum of 39 subjects
was required. The sample size was increased by 3 subjects to account for potential participant
Eligible participants were computer randomized and received either subcutaneous certolizumab
pegol 400gm or placebo (sterile saline) in a 2:1 ratio at weeks 0, 2, 4, and 8. The study drug and
placebo were provided in ready to use syringes that were identical other than the blinded ID
number on the side of the syringe.

Statistical analysis
Any patient who withdrew from the study, for whatever reason, was classified as a nonresponder.
All statistical summaries and 2-sample t-tests were performed using the Data Desk®
version 6.3. Comparison of these changes between treatment groups are also shown as 95%
confidence intervals (CI). The chi-square test or Fisher’s exact test was applied to analyze
baseline demographics, improvement with GRA treatment responders, and the proportion of
patients with a reduction from baseline of 30% or greater in their pain intensity score between
treatment groups.

Document preview Statistical Analysis Plan.pdf - page 1/1

Related documents

statistical analysis plan
coenzyme q10 in early parkinson disease
ph research 12 14
statistical analysis plan
protocol certolizumab pegol for ic fda changes
top preworkout supplements

Related keywords